GoodRx Holdings, Inc. Q3 FY2025 earnings call

Management Statement and Operational Highlights

• Partnerships and Programs: Expanded access and affordability programs with manufacturers (e.g., Novo Nordisk, Amgen), strengthened partnership with Kroger to launch RxSmartSaver counter solution, and launched new brand campaign 'Savings Wrangler' to reinforce brand trust.
• Subscription Offerings: Progressed with initiatives like GoodRx for hair loss and an upcoming weight loss subscription program, leveraging e-commerce capabilities for seamless digital experiences.
• Market Shift: Highlighted the U.S. healthcare environment shift toward transparency and direct-to-consumer access, positioning GoodRx as well-suited to lead given its platform reach and operational capabilities.

Segment Performance

• Manufacturer Solutions: Revenue for the quarter was $43.4 million, representing 54% year-over-year growth. This segment is driven by expanding partnerships with manufacturers like Novo Nordisk (offering Ozempic and Wegovy at $499 per month) and Amgen (Repatha nearly 60% off retail price), with over 200 brand affordability programs on the platform, nearly 80 of which are cash prices.
• Prescription Marketplace: Prescription transaction revenue was down 9% year-over-year, primarily due to Rite Aid store closures and lower transaction volume in the integrated savings program with a PBM partner.

Guidance

• Full year revenue expected above prior year or at least $792 million; fourth quarter revenue expected to decline sequentially due to accelerated manufacturer solutions deals.
• Full year adjusted EBITDA projections unchanged, representing 2%-6% growth from 2024 with margin in line with year-to-date trend.
• Manufacturer Solutions projected to have approximately 35% revenue growth in 2025.

Risks

• Ongoing impact of Rite Aid store closures on prescription volume.
• Uncertainty around future health insurance coverage affecting affordability.
• Regulatory and market dynamics influencing pharmaceutical pricing and access.

Question and Answer

• Q: Thoughts on stabilizing PTR environment and GoodRx's ability to win?

A: Chris and Wendy discussed macro conditions, PBM model evolution, and GoodRx's position as a complement to insurance.

• Q: PBM model evolution and impact on strategy?

A: Wendy and Chris noted PBMs rethinking point-of-sale pricing, with GoodRx already integrated and supportive.

• Q: Work with TrumpRx?

A: GoodRx is in active engagement with HHS to integrate, positioned to take advantage.

• Q: ISP partner interruption and outlook?

A: Wendy said it's a multi-network approach, with fine relationship continuing.

• Q: Manufacturer deals timing impact?

A: Chris explained some deals were accelerated, affecting Q3 vs Q4 revenue.

• Q: Marketing spend and customer acquisition cost?

A: Chris discussed marketing spend effectiveness and brand investment.

• Q: Manufacturing Solutions growth and reinvestment?

A: Chris and Wendy talked about reinvestment in capabilities to drive growth.

• Q: Rite Aid headwinds and recovery?

A: Chris and Wendy discussed recapture initiatives and counter solutions.